July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

Royalty buys PTC royalty stream
Royalty Pharma plc (NASDAQ:RPRX) is spending $650 million to acquire from PTC Therapeutics Inc. (NASDAQ:PTCT) about 43% its royalties for spinal muscular atrophy therapy risdiplam, to which the biotech's entitled to 8-16% on worldwide net sales. The therapy’s PDUFA date is Aug. 24.

CureVac tops off $640M raise
CureVac AG raised $126 million from Qatar Investment Authority, bringing its private funding round to $640 million. The financing includes previously disclosed investments from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and the German government (see “GSK-CureVac Deal”).
Fidelity leads Antengene C round ...